FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158992816> ?p ?o ?g. }

• W2158992816 endingPage "211" @default.
• W2158992816 startingPage "206" @default.
• W2158992816 abstract "In the current era, in inflammatory bowel disease step-up vs. top-down therapeutic approaches for the treatment of Crohn's disease (CD) are evaluated. As a consequence, we need to be able to differentiate between patients who will have more aggressive phenotypes to those with potentially more benign CD course. The former would require closer follow-up; however, more important might be the subgroup of patients to whom we want to offer biologic and immunomodulator therapy early on. This strategy is the only one supposed to prevent hospitalization and surgical intervention, specifically in patients with fistulae. Patients with expected fibrostenotic disease phenotype require early identification as well. The data regarding primary prevention of fibrostenosis are scarce; however, the association of biologic therapy with fewer surgeries might suggest that at least a subgroup of these patients would benefit from early, step-up therapeutic strategy. They might also benefit more from early immunomodulator therapy, as this was shown to have a secondary (though modest) preventive effect. The patients with fibrostenotic phenotype are also candidates for the most needed but still practically nonexistent anti-fibrotic therapies. In any case where patients are identified as having a higher chance to develop the more aggressive phenotypes, fibrostenotic and perforating, recommendation to avoid triggers/accelerators of disease progression (smoking, NSAIDS use) should be kept rigorously. Until recently, we based our attempts to predict disease phenotype mainly on clinical characteristics. As would be the case with many clinical features, some of them are not even predictors, but already manifestations of the condition we are trying to predict. Intervention at this stage might be too late for this patient. In addition to known demographic and clinical predictors reported, more recently sophisticated predictors shall be described. These predictors belong to three major groups: serologic markers, genetic markers, mucosal disease/healing. The major serologic markers used: anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), outer membrane porin C (OmpC), CBir1-flagellin, antibodies against I2 protein and the anti-glycan antibodies: anti-laminaribioside carbohydrate (ALCA), anti-chitobioside carbohydrate (ACCA) and anti-mannobioside carbohydrate (AMCA) and their associations with penetrating and fibrostenotic disease shall be discussed. The associations of genetic polymorphisms such as CARD15 and TLR4 variants and more aggressive disease phenotype will be described as well. Finally, the data supporting the relationship between inflamed, in contrast to healed intestinal mucosa and more aggressive disease course will be illustrated. These predictors may be used in clinical practice and/or research in order to better stratify CD prognosis. Thus they may be significant in our therapeutic decisions. Models for using these predictors would be presented." @default.
• W2158992816 created "2016-06-24" @default.
• W2158992816 creator A5029273084 @default.
• W2158992816 date "2009-01-01" @default.
• W2158992816 modified "2023-10-16" @default.
• W2158992816 title "Disease Behavior in Adult Patients: Are There Predictors for Stricture or Fistula Formation?" @default.
• W2158992816 cites W1537390954 @default.
• W2158992816 cites W1934147355 @default.
• W2158992816 cites W1975204619 @default.
• W2158992816 cites W1976789706 @default.
• W2158992816 cites W1976986819 @default.
• W2158992816 cites W1979014392 @default.
• W2158992816 cites W1984353725 @default.
• W2158992816 cites W1995864537 @default.
• W2158992816 cites W1996139830 @default.
• W2158992816 cites W2003278800 @default.
• W2158992816 cites W2022622803 @default.
• W2158992816 cites W2030421888 @default.
• W2158992816 cites W2031310375 @default.
• W2158992816 cites W2038515417 @default.
• W2158992816 cites W2048714549 @default.
• W2158992816 cites W2057759034 @default.
• W2158992816 cites W2059127937 @default.
• W2158992816 cites W2067694698 @default.
• W2158992816 cites W2085368011 @default.
• W2158992816 cites W2093655344 @default.
• W2158992816 cites W2100028493 @default.
• W2158992816 cites W2106048192 @default.
• W2158992816 cites W2115865518 @default.
• W2158992816 cites W2128570249 @default.
• W2158992816 cites W2133936908 @default.
• W2158992816 cites W2134617060 @default.
• W2158992816 cites W2142082253 @default.
• W2158992816 cites W2147324797 @default.
• W2158992816 cites W2148567965 @default.
• W2158992816 cites W2156050746 @default.
• W2158992816 cites W2165872127 @default.
• W2158992816 cites W2188248802 @default.
• W2158992816 cites W2986234337 @default.
• W2158992816 cites W2011393843 @default.
• W2158992816 cites W2116522000 @default.
• W2158992816 cites W2153757648 @default.
• W2158992816 cites W2483150229 @default.
• W2158992816 doi "https://doi.org/10.1159/000228551" @default.
• W2158992816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19786742" @default.
• W2158992816 hasPublicationYear "2009" @default.
• W2158992816 type Work @default.
• W2158992816 sameAs 2158992816 @default.
• W2158992816 citedByCount "19" @default.
• W2158992816 countsByYear W21589928162012 @default.
• W2158992816 countsByYear W21589928162013 @default.
• W2158992816 countsByYear W21589928162014 @default.
• W2158992816 countsByYear W21589928162015 @default.
• W2158992816 countsByYear W21589928162016 @default.
• W2158992816 countsByYear W21589928162018 @default.
• W2158992816 countsByYear W21589928162020 @default.
• W2158992816 countsByYear W21589928162021 @default.
• W2158992816 countsByYear W21589928162023 @default.
• W2158992816 crossrefType "journal-article" @default.
• W2158992816 hasAuthorship W2158992816A5029273084 @default.
• W2158992816 hasConcept C104317684 @default.
• W2158992816 hasConcept C118552586 @default.
• W2158992816 hasConcept C126322002 @default.
• W2158992816 hasConcept C127716648 @default.
• W2158992816 hasConcept C141071460 @default.
• W2158992816 hasConcept C177713679 @default.
• W2158992816 hasConcept C185592680 @default.
• W2158992816 hasConcept C2776341189 @default.
• W2158992816 hasConcept C2778260677 @default.
• W2158992816 hasConcept C2778384578 @default.
• W2158992816 hasConcept C2779134260 @default.
• W2158992816 hasConcept C2779280984 @default.
• W2158992816 hasConcept C2780665704 @default.
• W2158992816 hasConcept C3020646490 @default.
• W2158992816 hasConcept C55493867 @default.
• W2158992816 hasConcept C71924100 @default.
• W2158992816 hasConceptScore W2158992816C104317684 @default.
• W2158992816 hasConceptScore W2158992816C118552586 @default.
• W2158992816 hasConceptScore W2158992816C126322002 @default.
• W2158992816 hasConceptScore W2158992816C127716648 @default.
• W2158992816 hasConceptScore W2158992816C141071460 @default.
• W2158992816 hasConceptScore W2158992816C177713679 @default.
• W2158992816 hasConceptScore W2158992816C185592680 @default.
• W2158992816 hasConceptScore W2158992816C2776341189 @default.
• W2158992816 hasConceptScore W2158992816C2778260677 @default.
• W2158992816 hasConceptScore W2158992816C2778384578 @default.
• W2158992816 hasConceptScore W2158992816C2779134260 @default.
• W2158992816 hasConceptScore W2158992816C2779280984 @default.
• W2158992816 hasConceptScore W2158992816C2780665704 @default.
• W2158992816 hasConceptScore W2158992816C3020646490 @default.
• W2158992816 hasConceptScore W2158992816C55493867 @default.
• W2158992816 hasConceptScore W2158992816C71924100 @default.
• W2158992816 hasIssue "3" @default.
• W2158992816 hasLocation W21589928161 @default.
• W2158992816 hasLocation W21589928162 @default.
• W2158992816 hasOpenAccess W2158992816 @default.
• W2158992816 hasPrimaryLocation W21589928161 @default.
• W2158992816 hasRelatedWork W1493334061 @default.

• next